MARKET

BIAF

BIAF

bioAffinity Tech
NASDAQ
1.910
+0.090
+4.92%
Opening 11:28 02/27 EST
OPEN
1.850
PREV CLOSE
1.820
HIGH
2.060
LOW
1.850
VOLUME
23.23K
TURNOVER
0
52 WEEK HIGH
2.240
52 WEEK LOW
0.9548
MARKET CAP
18.15M
P/E (TTM)
-1.8698
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BIAF last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at BIAF last week (0212-0216)?
Weekly Report · 02/19 11:16
Weekly Report: what happened at BIAF last week (0205-0209)?
Weekly Report · 02/12 11:06
Weekly Report: what happened at BIAF last week (0129-0202)?
Weekly Report · 02/05 11:13
bioAffinity Technologies Implements New Incentive Plan and Bonuses
TipRanks · 02/01 09:34
Weekly Report: what happened at BIAF last week (0122-0126)?
Weekly Report · 01/29 11:03
bioAffinity Tech: Statement of changes in beneficial ownership of securities
Press release · 01/25 20:16
bioAffinity Technologies Announces Award Of Therapeutic Patent For Treatment Of Cancer; Indian Patent Office Grants Patent Related To Porphyrin Compounds For Targeted Cancer Treatment
Indian Patent Office Grants Patent Related to Porphyrin Compounds for Targeted Cancer Treatment. BioAffinity Technologies, Inc. Is a biotechnology company focused on the need for noninvasive, accurate tests for early-stage cancer and lung disease. The company's first product, CyPath® Lung, is a porphyr in-based diagnostic test for lung cancer.
Benzinga · 01/23 13:17
More
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company. The Company is focused on addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as a targeted cancer treatment. The Company develops noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Its lead product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. Through its wholly owned subsidiary, OncoSelect Therapeutics, LLC, the Company’s research is engaged in the discoveries and advancement of cancer therapeutics that specifically and selectively target cancer cells. It is focused on expanding its platform technologies in developing tests that detect and therapies that target various types of cancer and potentially other diseases.

Webull offers bioAffinity Technologies Inc stock information, including NASDAQ: BIAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIAF stock methods without spending real money on the virtual paper trading platform.